CXCL 9 and CXCL 10 as Sensitive Markers of Disease Activity in Patients with Rheumatoid Arthritis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective.: To assess whether serum levels of CC and CXC chemokines correlate with disease activity in patients with rheumatoid arthritis (RA), and to determine whether these effects predict clinical response. Methods.: Serum levels of the chemokines CC (CCL2, CCL5) and CXC (CXCL8, CXCL9, CXCL10) were quantified at baseline and after 12 weeks of treatment with disease-modifying antirheumatic drugs or biologic agents in 28 patients using flow cytometry. Serum from 40 healthy individuals was collected for comparison at baseline. Response to treatment was classified according to the European League Against Rheumatism (EULAR) response criteria. Remission of disease was defined as a Disease Activity Score < 2.6. Results.: The baseline serum concentrations of CC and CXC chemokines were significantly elevated in patients with active RA compared to healthy controls (p < 0.05) except for CCL2. Significant improvement in all disease activity measurements was observed after 12 weeks of treatment. Seventeen (60.7%) patients achieved good to moderate response based on the EULAR response criteria, and 5 (17.9%) patients achieved remission. The improvement in clinical activity in patients with RA was accompanied by a significant reduction in the serum concentration of CXCL9 and CXCL10 (p < 0.001). A significant reduction in the serum level of CXCL10 was also observed in the group that achieved EULAR response. Serum concentration of CCL5 remained significantly elevated in patients with RA (n = 5) who achieved remission compared to the healthy controls (p < 0.05). Conclusion.: Serum concentration of CXCL9 and CXCL10 may serve as sensitive biomarkers for disease activity in patients with RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995) · Science · doi:10.1126/science.270.5234.286 · Cited by 2,390
Interleukin-8 as a macrophage-derived mediator of angiogenesis
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135
The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis
Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27348 · Cited by 1,222
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742
Structure, Function, and Inhibition of Chemokines
Fernandez, E. J., & Lolis, E. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.091901.115838 · Cited by 609
Cited by
Regulation of Osteoclast Differentiation by Cytokine Networks
Amarasekara, D. S., Yun, H., Kim, S., Lee, N., Kim, H., & Rho, J. (2018) · Immune Network · doi:10.4110/in.2018.18.e8 · Cited by 518
“The levels of CXCL8, CXCL9, CXCL10, and CCL20 are elevated in inflammatory bone diseases (75,76).”
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y., & Liang, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686155 · Cited by 340
Tranilast: A review of its therapeutic applications
Darakhshan, S., & Pour, A. B. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2014.10.009 · Cited by 322
Crum, R. J., Hall, K., Molina, C. P., Hussey, G. S., Graham, E., Li, H., & Badylak, S. F. (2022) · npj Regenerative Medicine · doi:10.1038/s41536-022-00208-9 · Cited by 50
Fleischmann, R. M., Wagner, F., Kivitz, A. J., Mansikka, H. T., Khan, N., Othman, A. A., Khatri, A., Hong, F., Jiang, P., Ruzek, M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40319 · Cited by 32
Metadata
- Authors
- KUAN, W. P., TAM, L.-S., WONG, C.-K., KO, F. W. S., LI, T., ZHU, T., & LI, E. K.
- Venue
- The Journal of Rheumatology
- Publisher
- The Journal of Rheumatology
- Published
- 2009-12-23
- Volume
- 37
- Issue
- 2
- Pages
- 257-264
- ISSN
- 0315-162X (ISSN-L)
- 1499-2752
- OpenAlex
- W2076887678
- Cited by
- 95
- References
- 5
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.